No. The partnership runs month to month with 30 days’ notice, so there is no long-term lock-in. You’re allocated a guaranteed number of studies each month, and unused studies roll over, meaning there is no financial loss.
The model is designed to reduce costs, not increase them. Faster turnaround reduces roster delays and backfill expenses, 90%+ treatment compliance lowers repeat costs, and our compliance and coordination support reduces internal admin and risk.